News

MEDI-563, which was generated using BioWa’s Potelligent technology platform, has previously been investigated in a Phase I open-label dose-escalating study to evaluate the safety and tolerability of a

According to the company, this innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath Pap test slides to detect evidence

The multi-national study has enrolled more than 330 patients and is designed to assess the efficacy and safety of bevasiranib administered every eight or 12 weeks in preventing

Prior to NovaRx, Dr Russell was the president and CEO of Kalos Therapeutics, a biotechnology company focused on the development of cancer therapies. Before Kalos, Dr Russell served

Pursuant to the terms of the contract, the Provincial Government of the Western Cape (PGWC) will implement the new Enterprise Edition of the JAC Pharmacy Management system in

Eczacibasi Ilac Pazarlama (EIP) has agreed to obtain the necessary regulatory approvals for the territory and to pay Vical upfront and milestone payments plus a specified transfer price

The trial will assess the safety, tolerability and immunogenicity of the vaccine candidate in patients with solid tumors, including non-small cell lung cancer and prostate carcinoma. Merck is

AEterna Zentaris has received $52.5 million from Cowen Healthcare Royalty Partners (CHRP) at closing, less certain transaction costs. Under the terms of the agreement with CHRP, AEterna Zentaris

Mr Ford has over 20 years of experience at both biotechnology as well as major pharmaceutical companies. Mr Ford was most recently vice president of business development at